Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1981 1
1994 1
1997 2
2001 2
2002 1
2003 1
2005 3
2009 2
2010 5
2011 2
2012 3
2013 3
2014 3
2015 3
2016 5
2017 15
2018 10
2019 13
2020 19
2021 14
2022 10
2023 6
2024 9
2025 13

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

132 results

Results by year

Filters applied: . Clear all
Page 1
PPARγ-p53-Mediated Vasculoregenerative Program to Reverse Pulmonary Hypertension.
Hennigs JK, Cao A, Li CG, Shi M, Mienert J, Miyagawa K, Körbelin J, Marciano DP, Chen PI, Roughley M, Elliott MV, Harper RL, Bill MA, Chappell J, Moonen JR, Diebold I, Wang L, Snyder MP, Rabinovitch M. Hennigs JK, et al. Among authors: bill ma. Circ Res. 2021 Feb 5;128(3):401-418. doi: 10.1161/CIRCRESAHA.119.316339. Epub 2020 Dec 16. Circ Res. 2021. PMID: 33322916 Free PMC article.
A T cell receptor targeting a recurrent driver mutation in FLT3 mediates elimination of primary human acute myeloid leukemia in vivo.
Giannakopoulou E, Lehander M, Virding Culleton S, Yang W, Li Y, Karpanen T, Yoshizato T, Rustad EH, Nielsen MM, Bollineni RC, Tran TT, Delic-Sarac M, Gjerdingen TJ, Douvlataniotis K, Laos M, Ali M, Hillen A, Mazzi S, Chin DWL, Mehta A, Holm JS, Bentzen AK, Bill M, Griffioen M, Gedde-Dahl T, Lehmann S, Jacobsen SEW, Woll PS, Olweus J. Giannakopoulou E, et al. Among authors: bill m. Nat Cancer. 2023 Oct;4(10):1474-1490. doi: 10.1038/s43018-023-00642-8. Epub 2023 Oct 2. Nat Cancer. 2023. PMID: 37783807 Free PMC article.
Validation of the revised 2022 European LeukemiaNet risk stratification in adult patients with acute myeloid leukemia.
Ruhnke L, Bill M, Zukunft S, Eckardt JN, Schäfer S, Stasik S, Hanoun M, Schroeder T, Fransecky L, Steffen B, Krause SW, Scholl S, Hochhaus A, Sauer T, Kraus S, Schäfer-Eckart K, Kaufmann M, Jost E, Brümmendorf T, Schliemann C, Mikesch JH, Krug U, Hänel M, Morgner A, Schaich M, Neubauer A, Repp R, Niemann D, Seggewiss-Bernhardt R, Meinhardt A, Kullmer J, Kaiser U, Blau W, Kiani A, Grigoleit GU, Giagounidis A, Wurm AA, Altmann H, Middeke JM, Schetelig J, Müller-Tidow C, Stölzel F, Baldus CD, Platzbecker U, Serve H, Bornhäuser M, Thiede C, Röllig C. Ruhnke L, et al. Among authors: bill m. Blood Adv. 2025 Mar 25;9(6):1392-1404. doi: 10.1182/bloodadvances.2024013304. Blood Adv. 2025. PMID: 39504561 Free PMC article.
A quiescence-like/TGF-β1-specific CRISPRi screen reveals drug uptake transporters as secondary targets of kinase inhibitors in AML.
Rahimian E, Koochak M, Traikov S, Schroeder M, Brilloff S, Schäfer S, Kufrin V, Küchler S, Krüger A, Mirtschink P, Baretton G, Schröck E, Schewe DM, Ball CR, Bornhäuser M, Glimm H, Bill M, Wurm AA. Rahimian E, et al. Among authors: bill m. Drug Resist Updat. 2025 Jul;81:101242. doi: 10.1016/j.drup.2025.101242. Epub 2025 Mar 28. Drug Resist Updat. 2025. PMID: 40184725 Free article.
The histone modifier KAT2A presents a selective target in a subset of well-differentiated microsatellite-stable colorectal cancers.
Kufrin V, Seiler A, Brilloff S, Rothfuß H, Küchler S, Schäfer S, Rahimian E, Baumgarten J, Ding L, Buchholz F, Ball CR, Bornhäuser M, Glimm H, Bill M, Wurm AA. Kufrin V, et al. Among authors: bill m. Cell Death Differ. 2025 Jul;32(7):1259-1272. doi: 10.1038/s41418-025-01479-7. Epub 2025 Mar 27. Cell Death Differ. 2025. PMID: 40140561 Free PMC article.
Signaling-induced systematic repression of miRNAs uncovers cancer vulnerabilities and targeted therapy sensitivity.
Wurm AA, Brilloff S, Kolovich S, Schäfer S, Rahimian E, Kufrin V, Bill M, Carrero ZI, Drukewitz S, Krüger A, Hüther M, Uhrig S, Oster S, Westphal D, Meier F, Pfütze K, Hübschmann D, Horak P, Kreutzfeldt S, Richter D, Schröck E, Baretton G, Heining C, Möhrmann L, Fröhling S, Ball CR, Glimm H. Wurm AA, et al. Among authors: bill m. Cell Rep Med. 2023 Oct 17;4(10):101200. doi: 10.1016/j.xcrm.2023.101200. Epub 2023 Sep 20. Cell Rep Med. 2023. PMID: 37734378 Free PMC article.
VEXAS syndrome: complete molecular remission after hypomethylating therapy.
Sockel K, Götze K, Ganster C, Bill M, Georgi JA, Balaian E, Aringer M, Trautmann-Grill K, Uhlig M, Bornhäuser M, Haase D, Thiede C. Sockel K, et al. Among authors: bill m. Ann Hematol. 2024 Mar;103(3):993-997. doi: 10.1007/s00277-023-05611-w. Epub 2024 Jan 12. Ann Hematol. 2024. PMID: 38214707 Free PMC article.
132 results